Drug intelligence / Profile preview

AC-203

Development stage: Phase 3
Lead developer: TWi Biotechnology
Modality: Small Molecules
Administration: Topical

Overview

AC-203 is a topical formulation of 1% diacerein developed for treating Epidermolysis Bullosa (EB). It inhibits the activation of NLRP3 inflammasome and decreases the production of pro-inflammatory cytokines including IL-1beta and IL-18, which could reduce blister formation and severity of skin lesions in EB patients. The oral formulation containing diacerein has been approved for treating chronic rheumatic diseases in France and other EU and Middle Eastern countries since the mid-1990s.

Brand names: EBShield
Other names: diacerein 1% ointment

Targets

IL1B (Interleukin-1 beta)CASP1 (Caspase-1)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on AC-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC-203.

Explore the full profile